Providers have inadequate awareness of PCV20 vaccination recommendations

Two-thirds of well being care suppliers agree or strongly agree with increasing suggestions for the brand new 20-valent pneumococcal conjugate vaccine (PCV20), based on analysis revealed within the Sept. 8 concern of the U.S. Facilities for Illness Management and Prevention Morbidity and Mortality Weekly Report.

Noting there are gaps in well being care supplier information referring to understanding of the grownup pneumococcal vaccine suggestions, Rebecca Kahn, Ph.D., from the CDC in Atlanta, and colleagues performed a health care supplier information and attitudes survey to evaluate the feasibility and acceptability domains of the Advisory Committee on Immunization Practices (ACIP) Proof to Suggestions framework earlier than the October 2022 ACIP assembly.

The researchers discovered that two-thirds of the 751 supplier respondents agreed or strongly agreed with the coverage choice into consideration to develop the suggestions for the brand new PCV20 to adults who had solely acquired the beforehand really useful PCV13. Information gaps and implementation challenges in current suggestions have been recognized within the survey. At present, PCV20 is really useful for sure adults who’ve beforehand acquired PCV13, in addition to to those that haven’t been vaccinated.

“Gaps in information and challenges to implementing suggestions to be used of pneumococcal vaccines point out a necessity to extend supplier consciousness and implementation of the latest (October 2022) up to date pneumococcal vaccination suggestions and to offer instruments to help with patient-specific vaccination steerage,” the authors write.

Copyright © 2023 HealthDay. All rights reserved.